Stockscreener 앱 받기
24.16
1.64%
0.39
시장 영업 전:
24.24
0.08
+0.33%
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Definium Therapeutics Announces New Employee Inducement GrantsJune 15, 2026 - BioSpace
Definium Therapeutics (DFTX) director receives RSU and stock option grants - Stock Titan
Definium Therapeutics (DFTX) director awarded RSUs and stock options in new grant - Stock Titan
Definium Therapeutics (DFTX) awards RSUs and stock options to director Krebs - Stock Titan
Definium Therapeutics (DFTX) director granted RSUs and stock options in equity award - Stock Titan
Definium Therapeutics (DFTX) director granted RSUs and 19,188 stock options - Stock Titan
Six new Definium hires receive options on 155,480 shares - Stock Titan
Definium Therapeutics, Inc. Announces 2026 Annual Meeting Results and Key SEC Filings - Minichart
Definium Therapeutics (NASDAQ: DFTX) OKs 5M-share equity plan boost - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
How Approaching DT120 Phase III Readouts At Definium Therapeutics (DFTX) Have Changed Its Investment Story - Sahm
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
DFTX: Director elections, auditor appointment, and equity plan amendment approved; clinical trial results expected late Q2 - TradingView
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
A Look At Definium Therapeutics (DFTX) Valuation As Shares Show Strong Recent Momentum - Yahoo Finance
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Definium earnings on deck as pivotal psychedelic trial data looms By Investing.com - Investing.com Nigeria
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $44 - Moomoo
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Definium Therapeutics eyes key DT-120 depression data, advances anxiety program - MSN
Definium Therapeutics Inc (DFTX) Stock Price Quote Today & Current Price Chart | Capital.com UAE - Capital.com
Definium Therapeutics nears key depression drug trial results - MSN
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program - Yahoo Finance
Jefferies Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class Potential - Seeking Alpha
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
Definium Begins Second Phase 3 DT120 Trial As Valuation Gap Widens - Yahoo Finance
Definium Therapeutics Nears Pivotal Earnings Call Tests - The Globe and Mail
Definium Therapeutics convenes lawmakers and researchers to advance psychedelic medicine discourse - Traders Union
Definium Therapeutics Advances DT120 ODT for GAD and MDD With Promising Phase 3 Data and Billion-Dollar Market Potential - Minichart
Definium Highlights Late-Stage Psychedelic-Inspired Psychiatric Pipeline - TipRanks
Definium Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash - TradingView
Definium Therapeutics (NASDAQ: DFTX) maps DT120 Phase 3 path and 2026 data - Stock Titan
Definium Therapeutics presents pre-clinical safety data on new psychedelic treatment at APA meeting - Traders Union
Definium Therapeutics (DFTX) Institutional Ownership 2026 - MarketBeat
Trump's psychedelic drug order boosts investor interest with promise of faster reviews - Reuters
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
1.27%
1.43%
자본화:
|
볼륨(24시간):